Several classes of medication can lower high potassium levels, but the choice depends on how urgent the situation is. In an emergency, doctors use intravenous calcium to protect the heart, insulin and inhaled beta-agonists to push potassium into cells temporarily, and potassium-binding drugs or dialysis to actually remove it from the body. For chronic management, newer oral potassium binders and certain diuretics keep levels in check over weeks and months. The treatment landscape has shifted meaningfully in recent years, with two newer binders offering options that didn’t exist a decade ago.
Calcium for Cardiac Protection
When potassium climbs dangerously high, the first medication given is typically intravenous calcium gluconate. This does not actually lower potassium at all. Instead, it stabilizes the heart’s electrical activity, which high potassium can disrupt in life-threatening ways. Think of it as buying time while the drugs that actually reduce potassium levels kick in. One study found that calcium gluconate significantly improved major heart rhythm disturbances caused by hyperkalemia, though it did not fix all types of electrical abnormalities on an ECG.1PubMed Central. The effect of calcium gluconate in the treatment of hyperkalemia Treatment protocols generally call for calcium gluconate first, followed by insulin and beta-agonists to start moving potassium out of the bloodstream.2PubMed Central. Treatment and pathogenesis of acute hyperkalemia
The effect of calcium is fast, often working within minutes, but it wears off in about 30 to 60 minutes. That narrow window is why it is always paired with other treatments. If you’re in an emergency department with severely elevated potassium, the calcium IV is the very first thing going into your arm while the care team sets up everything else.
Medications That Shift Potassium Into Cells
The next line of treatment doesn’t remove potassium from your body either. Instead, these drugs shuffle it from your blood into your cells, where it’s less dangerous. This buys more time, usually a few hours, for longer-acting therapies to start working.
Insulin is the workhorse here. Typically given intravenously alongside glucose (to prevent blood sugar from dropping too low), insulin drives potassium into muscle and liver cells. It works within about 15 to 30 minutes and its effect can last a couple of hours. Nearly every hyperkalemia treatment protocol puts insulin near the top of the list after calcium.
Inhaled albuterol, the same medication used in asthma inhalers, is the other major potassium-shifting drug. It stimulates beta-2 receptors on cells, which activates a pump that pulls potassium inward. In patients with kidney failure, albuterol dropped serum potassium from about 5.6 to 4.5 within 30 minutes, and it worked even in diabetic patients whose insulin production was minimal.3PubMed. Potassium-lowering effect of albuterol for hyperkalemia in renal failure The doses used for hyperkalemia are much higher than a typical asthma puff, which is why this is done under medical supervision. The two drugs are often used together because their effects stack.
Sodium bicarbonate is a more debated option. Some physicians use it as an additional potassium shifter, but the evidence for it as a standalone treatment is thin. When researchers looked at whether adding bicarbonate to insulin made a meaningful difference, it did not produce a statistically significant extra drop in potassium levels.4The American Journal of Emergency Medicine. Sodium bicarbonate administration and subsequent potassium concentration in hyperkalemia treatment That said, some experts argue that bicarbonate still has a place in severe cases, particularly when metabolic acidosis is present, because correcting acidity can help potassium move back into cells.5PubMed Central. Treatment of Severe Hyperkalemia: Confronting 4 Fallacies It remains part of some treatment algorithms but not others.
Potassium Binders That Remove It Through the Gut
All the treatments above are temporary fixes. To actually get potassium out of your body, you need drugs that either force the kidneys to excrete more of it or trap it in the intestines so it leaves with stool. Potassium binders take the intestinal route.
The Older Resin
Sodium polystyrene sulfonate, sold under the brand name Kayexalate, has been around since the 1950s. It’s a resin that you swallow (or that’s given rectally). In the stomach, it releases sodium ions and picks up hydrogen ions; then as it moves through the intestines, it swaps hydrogen for potassium, carrying the potassium out when you have a bowel movement.6PubMed Central. Intestinal Necrosis due to Sodium Polystyrene Sulfonate (Kayexalate) in Sorbitol Potassium levels drop over a period of hours to days, so this isn’t a fast fix.
Kayexalate’s reputation has taken a beating over the decades. It was traditionally mixed with sorbitol to prevent constipation, but that combination has been linked to serious intestinal injuries, including colonic necrosis. Sorbitol appears to damage the gut lining directly and cause blood vessel spasms in the intestinal wall.7PubMed Central. Adverse Gastrointestinal Effects with Kayexalate or Kalimate: A Comprehensive Review More recent reports suggest that the resin itself may be toxic to the gut, not just the sorbitol it was paired with.8The American Journal of Medicine. Gastrointestinal Adverse Events with Sodium Polystyrene Sulfonate (Kayexalate) Use: A Systematic Review Despite these concerns, Kayexalate remains in use, partly because it’s cheap and familiar, and partly because newer alternatives weren’t available until recently.
The Newer Binders
Two newer potassium binders have changed the treatment landscape considerably. Patiromer (brand name Veltassa) is a polymer that exchanges calcium for potassium in the gut, increasing how much potassium leaves in stool. It is sodium-free, which matters for patients who need to limit sodium intake. Clinical trials showed it reliably lowered potassium in patients with chronic kidney disease, diabetes-related kidney problems, and heart failure, and it kept levels stable for up to a year.9PubMed. Patiromer: A Review in Hyperkalaemia
Sodium zirconium cyclosilicate (brand name Lokelma) works differently. It’s an inorganic crystal that preferentially grabs potassium and ammonium ions in the gut, exchanging them for hydrogen and sodium. In phase III studies, a three-times-daily dose brought potassium into the normal range within 48 hours, and a once-daily maintenance dose kept it there for up to four weeks.10PubMed Central. Sodium Zirconium Cyclosilicate: A Review in Hyperkalaemia One standout feature is speed: clinical trials showed it starts lowering potassium within an hour, though it is still not formally approved for treating acute emergencies.11PubMed. An evaluation of sodium zirconium cyclosilicate as a treatment option for hyperkalemia
A real-world Swedish study comparing the older resin to the newer binders found that patients on sodium polystyrene sulfonate and those on newer binders achieved similar potassium levels (averaging around 4.6 and 4.8 after 15 days, respectively). But patients stuck with the newer binders far longer: an average of 109 days versus 61 for the older resin, and about half of newer-binder users filled three or more consecutive prescriptions, compared to only 14% on Kayexalate.12PubMed Central. Evaluation of the introduction of novel potassium binders in routine care; the Stockholm CREAtinine measurements (SCREAM) project That gap in adherence strongly suggests better tolerability with the newer drugs.
Side Effects of the Newer Binders
Better tolerated doesn’t mean side-effect free. In a meta-analysis pooling data from trials of both newer binders, patiromer’s most common issues were gastrointestinal: about 8% of patients had constipation and around 5% had diarrhea. Low magnesium levels showed up in roughly 7% of users, a consequence of patiromer’s calcium-for-potassium exchange mechanism pulling out some magnesium along the way. Sodium zirconium cyclosilicate had a different side-effect profile, with urinary tract infections and mild swelling (edema) being the most reported issues, though both occurred in only about 1% of patients.13PubMed Central. Systematic Review and Meta-Analysis of Patiromer and Sodium Zirconium Cyclosilicate: A New Armamentarium for the Treatment of Hyperkalemia Neither binder showed the gut-necrosis risk that has haunted Kayexalate, which is a major practical improvement.
Drug Interaction Considerations
Because potassium binders work by grabbing ions in the gut, there’s an obvious concern: could they also grab other medications you’re taking and reduce their absorption? The answer is yes, sometimes, but the workaround is straightforward.
Patiromer was tested alongside 12 common drugs. Nine of them showed no meaningful change in absorption when taken at the same time. Ciprofloxacin was the biggest loser, with absorption dropping to about 72% of normal. Metformin and levothyroxine also showed modest reductions. The fix is simple: when patients took those medications three hours before the patiromer dose, absorption returned to normal for all of them.14PubMed Central. Evaluation of the Potential for Drug Interactions With Patiromer in Healthy Volunteers
Sodium zirconium cyclosilicate showed no interaction with amlodipine, glipizide, levothyroxine, or losartan when taken together. However, it did reduce blood levels of clopidogrel and dabigatran (both blood thinners) and altered levels of atorvastatin, furosemide, and warfarin.15Clinical Kidney Journal. Evaluation of potential drug interactions with sodium zirconium cyclosilicate The general prescribing advice for both binders is to separate them from other oral medications by a few hours when possible, especially blood thinners, antibiotics, and thyroid medications.
Diuretics and Renal Excretion
Your kidneys are the body’s main potassium disposal system, and certain diuretics can crank up how much potassium they flush out. Thiazide diuretics and loop diuretics like furosemide are the ones with a pronounced potassium-wasting effect, meaning they push extra potassium into the urine as part of how they work.16JAMA. Management of Potassium Problems During Long-Term Diuretic Therapy This is actually considered a side effect in most patients (and the reason doctors often check potassium levels in people taking these drugs for blood pressure or fluid retention). But in someone with chronically elevated potassium and at least some remaining kidney function, that “side effect” becomes a treatment tool.
Diuretics are not useful when the kidneys have largely shut down, because the drug needs functioning kidneys to work through. In those cases, the potassium binders or dialysis become the primary options.
Hemodialysis as a Last Resort
When potassium is dangerously high and the kidneys can’t be coaxed into excreting more, hemodialysis is the most definitive removal method. It physically filters potassium out of the blood. An expert panel reviewing emergency hyperkalemia management noted that most commonly used medications are at best temporary measures, and dialysis represents the most direct way to pull potassium from the body.17PubMed Central. Hyperkalemia management in the emergency department: An expert panel consensus The downside is that dialysis requires specialized equipment and vascular access, so it’s reserved for severe cases or patients already on dialysis for kidney failure. Some clinicians have debated whether low-potassium dialysate (the fluid used during dialysis) is safe or risks dropping levels too fast, but a review of the evidence concluded it remains both safe and effective for severe hyperkalemia.5PubMed Central. Treatment of Severe Hyperkalemia: Confronting 4 Fallacies
Medications That Cause High Potassium in the First Place
Sometimes the most important “treatment” is stopping or adjusting the drug that raised your potassium. A surprisingly long list of commonly prescribed medications can impair the kidneys’ ability to excrete potassium. The biggest offenders include ACE inhibitors, angiotensin receptor blockers (ARBs), NSAIDs like ibuprofen and naproxen, certain blood thinners including heparin, potassium-sparing diuretics like spironolactone, and the antibiotic trimethoprim.18PubMed. Drug-induced hyperkalemia Most drug-induced hyperkalemia stems from impaired renal potassium excretion rather than potassium being pushed out of cells.19The American Journal of Medicine. Drug-induced hyperkalemia: old culprits and new offenders
This creates a frustrating clinical dilemma. Many of these medications, especially ACE inhibitors, ARBs, and spironolactone, are lifesaving for people with heart failure or chronic kidney disease. Stopping them to fix the potassium problem can worsen the underlying disease. This is exactly where the newer potassium binders have carved out their most important role.
How Newer Binders Help People Stay on Heart and Kidney Medications
One of the most meaningful practical benefits of patiromer and sodium zirconium cyclosilicate is that they allow patients to keep taking RAAS inhibitors (the collective term for ACE inhibitors, ARBs, and drugs like spironolactone) that would otherwise need to be reduced or stopped because of rising potassium. A meta-analysis found that use of the newer potassium binders improved the odds of successfully optimizing spironolactone dosing by about 13%, cut the number of patients stuck on below-target doses, and reduced episodes of recurring hyperkalemia by more than half.20PubMed Central. The efficacy and safety of new potassium binders on renin-angiotensin-aldosterone system inhibitor optimization in heart failure patients A separate systematic review and meta-analysis reported that these newer binders improved overall RAAS inhibitor optimization by about 38% compared to placebo.21PubMed Central. Novel Potassium Binders in Reduction of Hyperkalemia and Optimization of RAAS Inhibitors Treatment in Patients with Chronic Kidney Disease or Heart Failure
In practical terms, this means fewer patients have to choose between controlling their potassium and taking the medications that protect their hearts and kidneys. Before these binders existed, doctors often had to down-titrate or discontinue drugs they knew were beneficial because potassium kept creeping up. The newer binders give clinicians more room to treat the whole patient rather than playing whack-a-mole with one lab value at the expense of another.
When High Potassium Isn’t Really High
Before any of these medications enter the picture, it’s worth knowing that not every elevated potassium result on a blood test is real. Pseudohyperkalemia, a falsely high reading, is more common than many people realize. It can happen when blood cells break open during the blood draw (hemolysis), when you clench your fist too hard with a tourniquet on, or when the blood sample sits too long before processing. Conditions involving very high white blood cell or platelet counts can also cause potassium to leak out of cells after the blood is drawn, producing an artificially elevated number.22The American Journal of Medicine. Pseudohyperkalemia: Three Cases and a Review of Literature
If a potassium result comes back high and you feel completely fine with no symptoms and no obvious reason for hyperkalemia, your doctor will usually repeat the blood draw with careful technique before starting treatment. Recognizing pseudohyperkalemia matters because treating a falsely elevated potassium can push your levels dangerously low.
Why ECG Findings Don’t Tell the Whole Story
You might assume an ECG (electrocardiogram) would reliably show whether high potassium is causing heart trouble, and many medical TV shows have reinforced that impression. The reality is murkier. A retrospective review found that the ECG was insensitive for diagnosing hyperkalemia. While the probability of seeing changes on the tracing increased as potassium rose, researchers could not establish a reliable diagnostic threshold. No particular T-wave height or pattern could definitively confirm or rule out dangerous hyperkalemia.23PubMed Central. Retrospective review of the frequency of ECG changes in hyperkalemia Case reports have described patients with markedly elevated potassium and completely normal-looking ECGs, particularly in people with chronic kidney disease whose hearts have adapted over time.
The clinical takeaway is that doctors generally make treatment decisions based on the actual potassium number and the overall clinical picture, not on whether the ECG looks alarming. An abnormal ECG can reinforce the urgency to act, but a normal-looking one doesn’t mean you’re in the clear.
Dietary Management Alongside Medication
For decades, patients with chronic kidney disease and high potassium have been told to avoid many fruits, vegetables, and other plant-based foods rich in potassium. That dietary restriction can lead to a bland, nutritionally poor diet that is hard to sustain. Researchers have started exploring whether potassium-lowering medications could allow patients to eat a healthier, plant-rich diet without their levels spiking. A clinical trial using sodium zirconium cyclosilicate alongside a prescribed healthy plant-based diet in kidney disease patients with hyperkalemia was designed specifically to test whether the medication could act as a safety net, letting people eat better without the potassium penalty.24Nephrology Dialysis Transplantation. #4456 HEALTHY PLANT-BASED DIET IN CHRONIC KIDNEY DISEASE THROUGH USE OF SODIUM ZIRCONIUM CYCLOSILICATE (HELPFUL TRIAL): RESULTS OF DIETARY INTAKE While this is still early-stage research, the concept represents a shift in thinking: rather than forcing patients into restrictive diets, medications might handle the excess potassium while people eat the foods known to be good for long-term health.
Diet alone is rarely enough to manage significantly elevated potassium, but it plays a supporting role alongside medication, particularly for chronic management. Reducing intake of very high-potassium foods like bananas, potatoes, and tomato sauce can help keep levels from climbing between doses of a binder. The goal for most patients is a balanced approach rather than extreme restriction.